TargetBeta
PRMT5
protein arginine methyltransferase 5 · also SKB1Hs, HRMT1L5, SKB1 · 7BS protein arginine methyltranferases
10 programs in company-led studies act on PRMT5, from 10 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| navlimetostat | Bristol-Myers Squibb | phase 3 | 1010 running | – | a judged reading |
| JBI-778rule | Jubilant Therapeutics India | phase 2 | 22 running | – | the studies' text |
| PRMT5 Inhibitor AZD3470 | AstraZeneca | phase 2 | 22 running | – | a judged reading |
| PRMT5 Inhibitor BAY 3713372rule | Bayer | phase 2 | 11 running | – | NCIt |
| PRMT5 Inhibitor TNG456rule | Tango Therapeutics | phase 2 | 11 running | – | NCIt |
| PRMT5 Inhibitor BGB-58067rule | BeOne Medicines | phase 1 | 22 running | – | NCIt |
| onametostatrule | Johnson & Johnson | phase 1 | 21 running | – | NCIt |
| PRMT5 Inhibitor SH3765rule | Nanjing Sanhome Pharmaceutical | phase 1 | 21 running | – | NCIt |
| PEP08rule | PharmaEngine | phase 1 | 11 running | – | the studies' text |
| PRMT5 Inhibitor IDE892rule | IDEAYA Biosciences | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 3 programs
- Adenocarcinoma Of Esophagus, 1 program
- Brain Neoplasms, 1 program
- Breast Neoplasms, 1 program
- Carcinoma, Adenoid Cystic, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Lung Neoplasms, 1 program
- Lymphoma, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Meningeal Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 5, 2026navlimetostat · Bristol-Myers Squibb · phase 3 · NCT07777133
- Mar 31, 2027PRMT5 Inhibitor TNG456 · Tango Therapeutics · phase 2 · NCT06810544
- Jun 30, 2027PRMT5 Inhibitor SH3765 · Nanjing Sanhome Pharmaceutical · phase 1 · NCT07557004
- Jul 1, 2027PRMT5 Inhibitor BGB-58067 · BeOne Medicines · phase 1 · NCT07712640
- Dec 2027PEP08 · PharmaEngine · phase 1 · NCT06973863
- Jan 19, 2028onametostat · Johnson & Johnson · phase 1 · NCT06788509
- Mar 2028JBI-778 · Jubilant Therapeutics India · phase 2 · NCT07755397
- Apr 30, 2028PRMT5 Inhibitor IDE892 · IDEAYA Biosciences · phase 1 · NCT07277413
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.